Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on October 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 11/2/2026.
- Purchased $1,001 - $15,000 in shares of argenex NASDAQ: ARGX on 10/27/2026.
- Sold $1,001 - $15,000 in shares of Illumina NASDAQ: ILMN on 10/27/2026.
- Sold $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 10/27/2026.
- Sold $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 10/27/2026.
- Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 10/27/2026.
- Purchased $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 10/27/2026.
- Sold $1,001 - $15,000 in shares of Micron Solutions OTCMKTS: MICR on 10/21/2026.
- Sold $1,001 - $15,000 in shares of Ciena NYSE: CIEN on 10/21/2026.
- Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 10/21/2026.
Insulet Trading Up 1.3%
PODD stock opened at $150.03 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company's 50-day simple moving average is $142.08 and its 200 day simple moving average is $174.71. The company has a market capitalization of $10.41 billion, a PE ratio of 24.43, a price-to-earnings-growth ratio of 1.13 and a beta of 1.06.
Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to analysts' expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company's quarterly revenue was up 19.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.24 EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 6.75 earnings per share for the current year.
Institutional Investors Weigh In On Insulet
Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. purchased a new stake in shares of Insulet in the third quarter worth about $77,000. GW&K Investment Management LLC boosted its stake in shares of Insulet by 74.6% in the 3rd quarter. GW&K Investment Management LLC now owns 695 shares of the medical instruments supplier's stock valued at $91,000 after purchasing an additional 297 shares in the last quarter. Private Wealth Asset Management LLC bought a new position in shares of Insulet during the third quarter valued at about $266,000. Westpac Banking Corp bought a new position in Insulet during the 3rd quarter worth approximately $82,000. Finally, Private Advisor Group LLC bought a new position in shares of Insulet in the third quarter worth approximately $226,000.
Wall Street Analysts Forecast Growth
PODD has been the topic of a number of research reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Insulet in a research note on Monday, September 21st. TD Cowen restated a "hold" rating on shares of Insulet in a research report on Wednesday, November 4th. Leerink Partners raised their price target on shares of Insulet from $143.00 to $167.00 and gave the stock a "market perform" rating in a report on Thursday, November 5th. Royal Bank Of Canada boosted their price objective on Insulet from $160.00 to $180.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. Finally, Canaccord Genuity Group decreased their price objective on Insulet from $249.00 to $179.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $185.67.
Check Out Our Latest Analysis on PODD
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Insulet
(
Get Free Report)
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
